Chinese Journal of Pharmacovigilance ›› 2017, Vol. 14 ›› Issue (6): 346-349.

Previous Articles     Next Articles

Application of Improved Weighted Association Rule Algorithm in Identifying the Risk of Pharmaceutical Production

Sun Yiyuan1, Deng Jianxiong2, Yang Yue1,*   

  1. 1 College of Business Administration, Shenyang Pharmaceutical University, Liaoning Shenyang,110016, China;
    2 Center for ADR Monitoring of Guangdong, Guangdong Guangzhou, 510080, China
  • Received:2017-05-05 Revised:2017-08-17 Online:2017-06-20 Published:2017-08-17

Abstract: Objective To improve the weighted association rule algorithm, and establish enterprise risk monitoring model. Methods Based on the theory of Apriori association rule algorithm, the category of organ damage, such as "liver damage" and "kidney damage", is used as the association rule item, and the serious events or the new adverse events are used as the weight index of association rules, in order to further improve the weighted association rule algorithm. Besides, we use the ADR report data received by the Guangdong Provincial Adverse Reaction Monitoring Center from January to June 2006 to identify the risk of "Qiqihar Second Pharmaceutical Factory Drug Safety Event" and verify the feasibility of the enterprise risk monitoring model. Results In the case of minimum support of 0.05 and minimum confidence of 0.90, the improved weighted Apriori correlation algorithm identifies the risk of " Qiqihar Second Pharmaceutical Factory Drug Safety Event ", while the traditional Apriori correlation algorithm has no risk signal generation; reduces the minimum support to 0.02 , although the traditional algorithm come up to risk signal, but there have been a lot of mixed risk signal as well. Conclusion Compared with the traditional weighted correlation algorithm, the improved weighted correlation model is highly effective and accurate, and is more conducive to the early warning and monitoring of production risk.

Key words: Apriori association rule, weighted association rule, risk early-warning model, adverse reaction monitoring.

CLC Number: